▲Pamicel CI
Pamicel’s allogeneic mesenchymal stem cell therapy Cellgram-AKI is being used to treat a novel coronavirus infection (Corona 19), while two more severely ill patients recovered.
According to Pamicel on the 22nd, a total of four seriously ill patients, including two cured patients in April of last year, have recovered through Cellgram-AKI.
“The two patients who received Cellgram-AKI this time also had acute respiratory distress syndrome (ARDS) until immediately before the treatment, and they continued to have hypoxia, so they were very serious enough to have intubation and mechanical ventilation.” It is improving with only one dose and is showing a stable state.”
Pamicel’s Cellgram-AKI has been approved for treatment of severe pneumonia in patients infected with Corona 19, so it is provided to many patients according to the current domestic situation where the number of’severe patients’ is decreasing due to the government’s active quarantine measures. It has not been done. However, as it shows a high therapeutic effect to patients receiving treatment, Pamicel continues to maintain the state of use of the treatment.
In particular, mesenchymal stem cells exert cell regeneration and immunological regulation to produce a strong anti-inflammatory effect throughout the body. Therefore, it is explained that it can be helpful to patients with significant impairment of lung function or patients with severe lung function after staying in the intensive care unit for a long time. to be. Famicel sends and supports documents requiring approval to the hospital institution ethics committee (IRB) immediately upon request of the doctor in charge, so that the treatment can be supplied quickly.
On the other hand, Cellgram-AKI is an allogeneic mesenchymal stem cell therapy to prevent acute kidney damage. However, it is determined that stem cells can be effective in preventing symptoms from worsening due to cytokine storms through anti-inflammatory action, and Famicel approved’therapeutic use approval’ in March last year for the treatment of severe pneumonia in patients infected with COVID-19. Licensed.
In the context of a global pandemic, it takes a lot of time to go through the usual clinical trial procedures, so we chose a method that can promptly receive approval and provide treatments to patients immediately.
In fact, interest in stem cell therapy continues as a number of clinical results and papers that have successfully used stem cells to treat COVID-19 patients in the US, China, and Israel are currently being published.